Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery

The epidermal growth factor–epidermal growth factor receptor (EGF-EGFR) pathway has become the main focus of selective chemotherapeutic intervention. As a result, two classes of EGFR inhibitors have been clinically approved, namely monoclonal antibodies and small molecule kinase inhibitors. Despite...

Descripción completa

Detalles Bibliográficos
Autores principales: Furman, Olga, Zaporozhets, Alisa, Tobi, Dror, Bazylevich, Andrii, Firer, Michael A., Patsenker, Leonid, Gellerman, Gary, Lubin, Bat Chen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318536/
https://www.ncbi.nlm.nih.gov/pubmed/35890400
http://dx.doi.org/10.3390/pharmaceutics14071505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318536/
https://www.ncbi.nlm.nih.gov/pubmed/35890400
http://dx.doi.org/10.3390/pharmaceutics14071505

Ejemplares similares